Proteogenomic Characterization of Bladder Cancer Reveals Sensitivity to Apoptosis Induced by Tumor Necrosis Factor-related Apoptosis-inducing Ligand in FGFR3-mutated Tumors.

[1]  Y. Allory,et al.  FGFR3 Mutational Activation Can Induce Luminal-like Papillary Bladder Tumor Formation and Favors a Male Sex Bias. , 2022, European urology.

[2]  M. Rubin,et al.  The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs-Part B: Prostate and Urinary Tract Tumors. , 2022, European urology.

[3]  N. Xu,et al.  Integrated proteogenomic characterization of urothelial carcinoma of the bladder , 2022, Journal of Hematology & Oncology.

[4]  L. Ding,et al.  Cancer proteogenomics: current impact and future prospects , 2022, Nature Reviews Cancer.

[5]  A. Ravaud,et al.  BLADDER CANCER: ESMO CLINICAL PRACTICE GUIDELINE FOR DIAGNOSIS, TREATMENT AND FOLLOW-UP†. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  A. Masson-Lecomte,et al.  European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). , 2021, European urology.

[7]  F. Radvanyi,et al.  Triple extraction method enables high quality mass spectrometry‐based proteomics and phospho‐proteomics for eventual multi‐omics integration studies , 2021, Proteomics.

[8]  R. Montironi,et al.  Molecular Pathology of Urothelial Carcinoma. , 2021, Human pathology.

[9]  N. Malats,et al.  An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer , 2021, Nature Communications.

[10]  L. Staudt,et al.  The next horizon in precision oncology: Proteogenomics to inform cancer diagnosis and treatment , 2021, Cell.

[11]  F. Radvanyi,et al.  Identification of new driver and passenger mutations within APOBEC-induced hotspot mutations in bladder cancer , 2020, Genome medicine.

[12]  J. Witjes,et al.  European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. , 2020, European urology.

[13]  Guo Ci Teo,et al.  Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma , 2019, Cell.

[14]  R. Huddart,et al.  Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. , 2019, The New England journal of medicine.

[15]  G. Mills,et al.  Breast cancer quantitative proteome and proteogenomic landscape , 2019, Nature Communications.

[16]  Mauro A. A. Castro,et al.  A Consensus Molecular Classification of Muscle-invasive Bladder Cancer , 2019, European urology.

[17]  Emmanuel Barillot,et al.  Aberrant ERBB4-SRC Signaling as a Hallmark of Group 4 Medulloblastoma Revealed by Integrative Phosphoproteomic Profiling. , 2018, Cancer cell.

[18]  Q. Mo,et al.  Prognostic Power of a Tumor Differentiation Gene Signature for Bladder Urothelial Carcinomas , 2018, Journal of the National Cancer Institute.

[19]  J. Marioni,et al.  Multi‐Omics Factor Analysis—a framework for unsupervised integration of multi‐omics data sets , 2018, Molecular systems biology.

[20]  M. Höglund,et al.  A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort , 2018, Scientific Reports.

[21]  F. Radvanyi,et al.  An FGFR3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers , 2018, EMBO molecular medicine.

[22]  Olivia Alder,et al.  Genomic Subtypes of Non-invasive Bladder Cancer with Distinct Metabolic Profile and Female Gender Bias in KDM6A Mutation Frequency. , 2017, Cancer cell.

[23]  Steven J. M. Jones,et al.  Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer , 2017, Cell.

[24]  P. Laurent-Puig,et al.  Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression , 2016, Genome Biology.

[25]  Ronald J. Moore,et al.  Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer , 2016, Cell.

[26]  Michael L. Gatza,et al.  Proteogenomics connects somatic mutations to signaling in breast cancer , 2016, Nature.

[27]  A. Adjei,et al.  A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma , 2015, Molecular Cancer Therapeutics.

[28]  J. Witjes,et al.  Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: a systematic review , 2015 .

[29]  P. Gestraud,et al.  Independent component analysis uncovers the landscape of the bladder tumor transcriptome and reveals insights into luminal and basal subtypes. , 2014, Cell reports.

[30]  Xavier Paoletti,et al.  EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype , 2014, Science Translational Medicine.

[31]  Jeffrey R. Whiteaker,et al.  Proteogenomic characterization of human colon and rectal cancer , 2014, Nature.

[32]  Katherine A. Hoadley,et al.  Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology , 2014, Proceedings of the National Academy of Sciences.

[33]  K. Baggerly,et al.  Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. , 2014, Cancer cell.

[34]  S. Morris,et al.  Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP) inhibitor, in patients (Pts) with advanced solid tumors: Results of a phase I study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  W. Krol,et al.  TRAIL-induced apoptosis and expression of death receptor TRAIL-R1 and TRAIL-R2 in bladder cancer cells. , 2010, Folia histochemica et cytobiologica.

[36]  M. Mann,et al.  Super-SILAC mix for quantitative proteomics of human tumor tissue , 2010, Nature Methods.

[37]  Ronald B. Moore,et al.  Response of bladder carcinoma cells to TRAIL and antisense oligonucleotide, Bcl-2 or clusterin treatments. , 2009, The Journal of urology.

[38]  J. Southgate,et al.  Differential susceptibility to TRAIL of normal versus malignant human urothelial cells , 2006, Cell Death and Differentiation.

[39]  A. Spencer,et al.  TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy , 2001, Leukemia.

[40]  C. Abbou,et al.  Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. , 2001, The American journal of pathology.

[41]  A. Vlahou,et al.  Proteome‐based classification of Nonmuscle Invasive Bladder Cancer , 2019, International journal of cancer.

[42]  T. Griffith,et al.  Sensitization of human bladder tumor cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis with a small molecule IAP antagonist , 2010, Apoptosis.